Bosentan
بوسنتان
❤️ Cardiovascular SystemEndothelin receptor antagonist
Market / country: 🇺🇸 USA
Tracleer (US)
🧮 Dose calculator
Pulmonary arterial hypertension (PAH) · Regimen source: FDA Tracleer · 2.2, Table 1
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Pregnancy. FDA Tracleer · 4.1
- ⛔ Concomitant cyclosporine A. FDA Tracleer · 4.2
- ⛔ Concomitant glyburide (glibenclamide). FDA Tracleer · 4.3
- ⛔ Hypersensitivity to bosentan (DRESS, anaphylaxis, angioedema). FDA Tracleer · 4.4
Warnings
- • Boxed warning: hepatotoxicity — liver enzymes before starting and monthly; available only through REMS. FDA Tracleer · Boxed WarningFDA Tracleer · 2.1
- • Boxed warning: embryo-fetal toxicity — contraindicated in pregnancy; pregnancy test before and monthly, effective contraception until 1 month after stopping (REMS). FDA Tracleer · Boxed Warning
- • Fluid retention; pulmonary oedema with veno-occlusive disease; decreased sperm counts; haemoglobin decrease. FDA Tracleer · 5
Formulations
- 62.5 mg tablet — tablet 🇺🇸 USA FDA Tracleer · 3
- 125 mg tablet — tablet 🇺🇸 USA FDA Tracleer · 3
- 32 mg tablet for oral suspension (scored) — tablet 🇺🇸 USA FDA Tracleer · 3
👥 Special populations
- 🤰 PregnancyContraindicated
Label: contraindicated in pregnancy. FDA Tracleer · 4
“Hypersensitivity ( 4.4 ). 4.1 Pregnancy Use of TRACLEER is contraindicated in females who are pregnant [see Boxed Warning , Dosage and Administration (2.1) , Warnings and Precautions (5.3) , Use in Specific Populations (8.1) ] . 4.2 Use with Cyclosporine A Co-administration of cyclosporine A and bosentan resulted in …”
- 🤱 BreastfeedingDangerous / avoid
Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Tracleer · 8.2
“Because of the potential for serious adverse reactions, such as fluid retention and hepatotoxicity, in breastfed infants from TRACLEER, advise women not to breastfeed during treatment with TRACLEER.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Tracleer · 8.4
“The efficacy of TRACLEER in patients <18 years is supported by data from an uncontrolled trial in which 19 pediatric patients were treated with TRACLEER.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Tracleer · 8.5
“Clinical studies of TRACLEER did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger subjects.”
- ⚥ Females & males of reproductive potentialUse with caution
Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Tracleer · 8.3
“Contraception Drug interaction studies show that bosentan reduces serum levels of the estrogen and progestin in oral contraceptives.”
🔗 Reference links
- FDA (approval record)NDA021290
- DailyMed (FDA label)FDA Tracleer
- MedlinePlus (NIH)Bosentan
- WHO ATC/DDDC02KX01
- Darooyab (Iran)Bosentan
🇮🇷 Registered in Iran Darooyab · G-1563/Bosentan
Dosage forms with Iranian generic codes, per Darooyab.
- 07848 · BOSENTAN 125MG TAB · قرص بوسنتان ۱۲۵ میلیگرم
- 12114 · BOSENTAN 62.5MG TAB · قرص بوسنتان ۶۲٫۵ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Tracleer · 3FDA Tracleer · 2.2, Table 1FDA Tracleer · 2.2FDA Tracleer · 4.1FDA Tracleer · 4.2FDA Tracleer · 4.3FDA Tracleer · 4.4FDA Tracleer · Boxed WarningFDA Tracleer · 2.1FDA Tracleer · 5FDA Tracleer · SPL approval / marketing categoryFDA Tracleer · 4FDA Tracleer · 8.2FDA Tracleer · 8.4FDA Tracleer · 8.5FDA Tracleer · 8.3
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-1563/Bosentan
- Clinical review⚠ Unverified